Our policy on clinical research

Research NHS Icon

Contact us

Get in touch with our policy team to find out more information about our work and our policies.

Email the team

Medical research is vital if the UK is going to enjoy continued improvements to health. Research allows us to understand diseases better, diagnose earlier, and deliver improved outcomes with fewer side effects from treatment.

Clinical research, including trials, plays a critical role in translating scientific discoveries into safer, kinder, and more effective cancer diagnostics and treatments. As a research funder and an advocate for cancer patients, Cancer Research UK has a strong interest in ensuring that clinical research has the conditions to thrive.

To achieve this, our policy team work closely with patients, health service staff, researchers, and other organisations to raise the profile of clinical research within Government and develop policies to help make the UK a more attractive place to conduct and take part in research.

Driven by the remarkable achievements of those delivering clinical trials during the pandemic, clinical research is currently a key priority for the Government – with strong representation in multiple Government strategies.

Related documents

2023 Survey of the UK Clinical Research Workforce - Full Report (February 2024)

Our response to a Lords Science and Technology Committee Inquiry into Clinical Academics in the NHS (December 2022)

Beyond recovery - The case for transforming UK clinical cancer research (February 2022)

State of the cancer research workforce survey (February 2022)

Creating Time for Research full report  and the supplementary survey  (February 2021)

CRUK supporting statement for RCP case for research (December 2019)

Response to Chief Scientist Office Consultation on Proposed Changes to the Support Structures for NHS Research in Scotland

Cancer Research UK’s response to the MHRA No Deal consultation (November 2018)

Cancer Research UK’s policy statement on clinical trials as the UK exits the EU (August 2018)

The Future of Clinical Trials After Brexit report (August 2018) 

The Future of Clinical Trials After Brexit slide deck (August 2018)

Response to House of Commons Science and Technology Inquiry: Brexit, Science and Innovation Summit (February 2018)

Response to Scottish Parliament Health and Sport Committee inquiry: Impact of leaving the European Union on health and social care in Scotland (January 2018)

Cancer Research UK’s policy statement on alignment with the EU Clinical Trial Regulation (December 2017)

Response to House of Commons Health Select Committee Brexit Inquiry (October 2017)

Response to Consultation on Expansion of Undergraduate Medical Education (June 2017)

Regulation and governance of health research: five years on - full report (June 2017)

Response to EU consultation on Paediatric Medicines Regulation (February 2017)

Response to EMA consultation on Good Pharmacogenomic Practice Guidance (August 2016) 

Response to House of Commons inquiry into leaving the EU: implications and opportunities for science and research (August 2016)

Response to EU consultation on Ethical considerations for clinical trials on medicinal products conducted with minors (August 2016)

Response to EU consultation on Definition of Investigational Medicinal Products (IMPs) and use of Auxiliary Medicinal Products (AMPs) (August 2016)

Response to EU consultation on Risk proportionate approaches in clinical trials (August 2016)

Response to EU consultation on Summary of clinical trial results for laypersons (August 2016)

Response to MHRA consultation on Guidance for companion in-vitro diagnostic tests (July 2016)

Every patient a research patient? (May 2015)

Response to NIHR Clinical Research Network consultation on proposals for the designation of clinical themes (February 2013)

Join us on Twitter/X

Join the conversation and follow @CRUK_Policy for news, updates and opinion.


Last reviewed